Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

JAIN, NITIN

One or more keywords matched the following items that are connected to JAIN, NITIN

Item Type	Name
Academic Article	Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
Academic Article	A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.
Academic Article	Chronic lymphocytic leukemia with deletion 17p: emerging treatment options.
Academic Article	Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.
Academic Article	Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia.
Academic Article	Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.
Academic Article	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
Academic Article	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
Academic Article	Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
Academic Article	Î²₂-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia
Academic Article	Chronic lymphocytic leukemia with deletion 17p
Academic Article	Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia
Academic Article	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens
Academic Article	Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
Academic Article	?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Academic Article	Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab.
Academic Article	Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Academic Article	Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
Academic Article	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.
Academic Article	Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells.
Academic Article	Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Academic Article	Duvelisib: a phosphoinositide-3 kinase d/? inhibitor for chronic lymphocytic leukemia.
Academic Article	Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report.
Academic Article	Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
Academic Article	Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
Academic Article	Update on signal inhibitors in chronic lymphocytic leukemia.
Academic Article	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.
Academic Article	Chronic Lymphocytic Leukemia: Diagnosis and Treatment.
Academic Article	STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells.
Academic Article	STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells.
Academic Article	Duvelisib, an oral dual PI3K-d,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
Academic Article	Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options.
Academic Article	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Academic Article	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Academic Article	A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
Academic Article	Optimizing drug dosing for the treatment of chronic lymphocytic leukemia.
Academic Article	STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.
Academic Article	The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant?
Academic Article	The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
Academic Article	Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
Academic Article	Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.
Academic Article	Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia.
Academic Article	CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
Academic Article	STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells.
Academic Article	Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Academic Article	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Academic Article	How I manage chronic lymphocytic leukemia.
Academic Article	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Academic Article	First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
Academic Article	Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis.
Academic Article	Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Academic Article	Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.
Academic Article	STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.
Academic Article	TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
Academic Article	Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.
Academic Article	Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
Academic Article	Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.
Academic Article	Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Academic Article	A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.

Search Criteria

Leukemia T Cell